Aurel Perren

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients
    Aurel Perren
    Department of Pathology, University Hospital, 8091 Zurich, Switzerland
    Oncogene 21:7605-8. 2002
  2. doi request reprint Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases
    Anja M Schmitt
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Surg Pathol 32:420-5. 2008
  3. ncbi request reprint WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors
    Anja M Schmitt
    Department of Pathology, Institute of Surgical Pathology, University of Zurich, Zurich, Switzerland
    Am J Surg Pathol 31:1677-82. 2007
  4. ncbi request reprint Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient
    Aurel Perren
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Surg Pathol 30:1047-51. 2006
  5. ncbi request reprint Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich, Switzerland
    Anticancer Res 24:2415-8. 2004
  6. doi request reprint VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease
    Matteo Montani
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Surg Pathol 34:806-15. 2010
  7. ncbi request reprint Molecular profiles of gastroenteropancreatic endocrine tumors
    Aurel Perren
    Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Virchows Arch 451:S39-46. 2007
  8. ncbi request reprint Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas
    Aurel Perren
    Institute of Surgical Pathology, Department of Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Clin Endocrinol Metab 92:1118-28. 2007
  9. ncbi request reprint Molecular genetics of gastroenteropancreatic endocrine tumors
    Aurel Perren
    Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Ann N Y Acad Sci 1014:199-208. 2004
  10. ncbi request reprint CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix
    Khaled O Alsaad
    Department of Pathology, University Health Network Toronto Medical Laboratories, University of Toronto, Ontario, Canada, and Institute of Clinical Pathology, Department of Pathologie, University Hospital, Zurich, Switzerland
    Int J Surg Pathol 15:252-7. 2007

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients
    Aurel Perren
    Department of Pathology, University Hospital, 8091 Zurich, Switzerland
    Oncogene 21:7605-8. 2002
    ..However, LOH alone could lead to a complete loss of function since SDHD is an imprinted gene. Furthermore, we describe two germline variants possibly causing hereditary paragangliomas...
  2. doi request reprint Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases
    Anja M Schmitt
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Surg Pathol 32:420-5. 2008
    ....
  3. ncbi request reprint WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors
    Anja M Schmitt
    Department of Pathology, Institute of Surgical Pathology, University of Zurich, Zurich, Switzerland
    Am J Surg Pathol 31:1677-82. 2007
    ..Our aim was to test retrospectively the predictive value of these 2004 WHO criteria and of CK19, CD99, COX2, and p27 immunohistochemistry in a large series of patients with long-term follow-up...
  4. ncbi request reprint Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient
    Aurel Perren
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Surg Pathol 30:1047-51. 2006
    ..Furthermore, the NF1 gene must be considered as a candidate tumor suppressor gene for sporadic insulinomas and probably other pancreatic endocrine tumors...
  5. ncbi request reprint Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich, Switzerland
    Anticancer Res 24:2415-8. 2004
    ..Distinction of Spitz nevus from malignant melanoma is sometimes difficult on the basis of conventional histology. A high rate of BRAF gene mutations in malignant melanomas (66%) and nevi (82%) has recently been reported...
  6. doi request reprint VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease
    Matteo Montani
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Surg Pathol 34:806-15. 2010
    ..Our in vivo results support a model in which renal cysts represent precursor lesions for clear cell renal cell carcinoma and arise from single renal tubular epithelial cells owing to von Hippel-Lindau gene deletion...
  7. ncbi request reprint Molecular profiles of gastroenteropancreatic endocrine tumors
    Aurel Perren
    Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Virchows Arch 451:S39-46. 2007
    ..It is therefore conceivable that the gastroenteropancreatic neuroendocrine tumors also differ in their molecular profile. This review summarizes and discusses the available data in this field...
  8. ncbi request reprint Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas
    Aurel Perren
    Institute of Surgical Pathology, Department of Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Clin Endocrinol Metab 92:1118-28. 2007
    ..To date, it is unknown whether small islet-like endocrine cell clusters found in MEN1 patients are neoplastic or rather hyperplastic. It is also unclear whether microadenomas develop from islets...
  9. ncbi request reprint Molecular genetics of gastroenteropancreatic endocrine tumors
    Aurel Perren
    Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Ann N Y Acad Sci 1014:199-208. 2004
    ..Molecular differences among various subtypes of gastroenteropancreatic endocrine tumors are highlighted in view of their role as indicators of separate genetic pathways...
  10. ncbi request reprint CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix
    Khaled O Alsaad
    Department of Pathology, University Health Network Toronto Medical Laboratories, University of Toronto, Ontario, Canada, and Institute of Clinical Pathology, Department of Pathologie, University Hospital, Zurich, Switzerland
    Int J Surg Pathol 15:252-7. 2007
    ..There is no difference in the immunostaining for CK19 and CD99 between GCCs and classic carcinoids, and both types of neuroendocrine tumor show the same extent of expression of both markers...
  11. ncbi request reprint Loss of heterozygosity at chromosome 6q23-25 correlates with clinical and histologic parameters in salivary gland adenoid cystic carcinoma
    Ingrid Stallmach
    Institute of Clinical Pathology, Department of Pathology, University of Zurich, Switzerland
    Virchows Arch 440:77-84. 2002
    ..The frequent occurrence of LOH at 6q23-25 and the correlation of LOH rates with prognostic parameters indicate that a prognostically important tumor suppressor gene is located in this chromosomal area...
  12. ncbi request reprint Familial pheochromocytomas and paragangliomas: stories from the sign-out room
    Aurel Perren
    Institute of Surgical Pathology, University Hospital Zurich, Switzerland
    Endocr Pathol 17:337-44. 2006
    ..A brief summary of phenotypes, the genes involved, and typical mutations in these syndromes is provided...
  13. ncbi request reprint Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors
    Gunter Kloppel
    Department of Pathology, University of Kiel, Michaelisstr 11, 24105, Kiel, Germany
    Virchows Arch 451:S9-27. 2007
    ..In addition, a tumor/nodes/metastases classification and a grading system are presented. In the light of these criteria, the various GEP-NET entities are reviewed...
  14. ncbi request reprint Hereditary neuroendocrine tumors of the gastroenteropancreatic system
    Martin Anlauf
    Department of Pathology, University of Kiel, Michaelisstr 11, 24105, Kiel, Germany
    Virchows Arch 451:S29-38. 2007
    ..In addition, GEP-NETs clustering in individual families or associated with other malignancies without known genetic background are discussed...
  15. ncbi request reprint The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification
    Gunter Kloppel
    Department of General Pathology, University of Kiel, Kiel, Germany
    Ann N Y Acad Sci 1014:13-27. 2004
    ..On the basis of localization and of various morphological and biological criteria, we distinguish between benign neuroendocrine tumors, tumors with uncertain malignant potential, and tumors showing low-grade and high-grade malignancy...
  16. ncbi request reprint Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors
    Gunter Kloppel
    Department of Pathology, University of Kiel, Michaelisstr 11, 24105, Kiel, Germany
    Endocr Pathol 18:150-5. 2007
    ..The endocrine cell hyperplasia in the colon described in inflammatory bowel disease has neither a genetic nor a definite hormonal background...
  17. ncbi request reprint A novel succinate dehydrogenase subunit B gene mutation, H132P, causes familial malignant sympathetic extraadrenal paragangliomas
    Margarete Maier-Woelfle
    Department of Internal Medicine, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Clin Endocrinol Metab 89:362-7. 2004
    ....
  18. ncbi request reprint DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors
    Aurel Perren
    Institute of Clinical Pathology, University of Zurich, Switzerland
    Diagn Mol Pathol 12:181-6. 2003
    ..Therefore, DPC4 inactivation by mutation or deletion appears to be very rare in PET, which confirms the current concept of unrelated mechanisms of tumorigenesis of endocrine versus exocrine pancreatic tumors...
  19. doi request reprint Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity
    Nele Garbrecht
    Department of Pathology, University of Kiel, Michaelisstr 11, Kiel, Germany
    Endocr Relat Cancer 15:229-41. 2008
    ..MEN1-associated SOM-NETs and GCPGs follow a benign course, while somatostatin-producing pdNECs are aggressive neoplasms. The occurrence of the so-called somatostatinoma syndrome appears to be extremely uncommon...
  20. ncbi request reprint Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma
    Esther Korpershoek
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, JNI room 222, PO Box 2040, 3000 CR Rotterdam, The Netherlands
    Endocr Relat Cancer 14:453-62. 2007
    ..We suggest that sequential mutation analysis should be directed first at RET, followed by VHL and SDHD for patients with bilateral adrenal PCC at diagnosis, and at SDHB and SDHD for patients with sPGL...